Rhinovirus-16 induced temporal interferon responses in nasal epithelium links with viral clearance and symptoms.
asthma
epithelium
innate immunity
interferon response
nasal epithelium
rhinovirus
virus
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
08
04
2019
revised:
27
06
2019
accepted:
30
07
2019
pubmed:
11
8
2019
medline:
20
9
2020
entrez:
11
8
2019
Statut:
ppublish
Résumé
The temporal in vivo response of epithelial cells to a viral challenge and its association with viral clearance and clinical outcomes has been largely unexplored in asthma. To determine gene expression profiles over time in nasal epithelial cells (NECs) challenged in vivo with rhinovirus-16 (RV16) and compare to nasal symptoms and viral clearance. Patients with stable mild to moderate asthma (n = 20) were challenged intranasally with RV16. Nasal brush samples for RNA sequencing were taken 7 days prior to infection and 3, 6 and 14 days post-infection, and blood samples 4 days prior to infection and day 6 post-infection. Viral load was measured in nasal lavage fluid at day 3, 6 and 14. Top differentially (>2.5-fold increase) expressed gene sets in NECs post-RV16 at days 3 and 6, compared with baseline, were interferon alpha and gamma response genes. Patients clearing the virus within 6 days (early resolvers) had a significantly increased interferon response at day 6, whereas those having cleared the virus by day 14 (late resolvers) had significantly increased responses at day 3, 6 and 14. Interestingly, patients not having cleared the virus by day 14 (non-resolvers) had no enhanced interferon responses at any of these days. The daily Cold Symptom Scores (CSS) peaked at days 3 to 5 and correlated positively with interferon response genes at day 3 (R = 0.48), but not at other time-points. Interferon response genes were also enhanced in blood at day 6 after RV16 challenge. This study shows that viral load and clearance varies markedly over time in mild to moderate asthma patients exposed to a fixed RV16 dose. The host's nasal interferon response to RV16 at day 3 is associated with upper respiratory tract symptoms. The temporal interferon response in nasal epithelium associates with viral clearance in the nasal compartment.
Sections du résumé
BACKGROUND
The temporal in vivo response of epithelial cells to a viral challenge and its association with viral clearance and clinical outcomes has been largely unexplored in asthma.
OBJECTIVE
To determine gene expression profiles over time in nasal epithelial cells (NECs) challenged in vivo with rhinovirus-16 (RV16) and compare to nasal symptoms and viral clearance.
METHODS
Patients with stable mild to moderate asthma (n = 20) were challenged intranasally with RV16. Nasal brush samples for RNA sequencing were taken 7 days prior to infection and 3, 6 and 14 days post-infection, and blood samples 4 days prior to infection and day 6 post-infection. Viral load was measured in nasal lavage fluid at day 3, 6 and 14.
RESULTS
Top differentially (>2.5-fold increase) expressed gene sets in NECs post-RV16 at days 3 and 6, compared with baseline, were interferon alpha and gamma response genes. Patients clearing the virus within 6 days (early resolvers) had a significantly increased interferon response at day 6, whereas those having cleared the virus by day 14 (late resolvers) had significantly increased responses at day 3, 6 and 14. Interestingly, patients not having cleared the virus by day 14 (non-resolvers) had no enhanced interferon responses at any of these days. The daily Cold Symptom Scores (CSS) peaked at days 3 to 5 and correlated positively with interferon response genes at day 3 (R = 0.48), but not at other time-points. Interferon response genes were also enhanced in blood at day 6 after RV16 challenge.
CONCLUSION AND CLINICAL RELEVANCE
This study shows that viral load and clearance varies markedly over time in mild to moderate asthma patients exposed to a fixed RV16 dose. The host's nasal interferon response to RV16 at day 3 is associated with upper respiratory tract symptoms. The temporal interferon response in nasal epithelium associates with viral clearance in the nasal compartment.
Identifiants
pubmed: 31400236
doi: 10.1111/cea.13481
pmc: PMC6972523
doi:
Substances chimiques
IFNG protein, human
0
Interferon-alpha
0
Interferon-gamma
82115-62-6
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1587-1597Informations de copyright
© 2019 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Références
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13562-7
pubmed: 18768794
Am J Respir Crit Care Med. 2012 Mar 1;185(5):508-16
pubmed: 22135341
J Allergy Clin Immunol. 2015 Jul;136(1):202-5
pubmed: 25784274
Mucosal Immunol. 2013 Jul;6(4):797-806
pubmed: 23212197
AMA Arch Intern Med. 1958 Feb;101(2):267-78
pubmed: 13497324
Clin Exp Allergy. 2014 Jun;44(6):813-21
pubmed: 24450586
Nat Med. 2017 Jun;23(6):681-691
pubmed: 28459437
Eur Respir J. 2012 Dec;40(6):1374-80
pubmed: 22441741
EBioMedicine. 2017 May;19:128-138
pubmed: 28373098
J Allergy Clin Immunol. 2019 Jan;143(1):442-447.e10
pubmed: 30296526
J Clin Microbiol. 2011 Jul;49(7):2631-6
pubmed: 21543571
Thorax. 2006 Feb;61(2):100-4
pubmed: 16443705
J Allergy Clin Immunol. 1996 Apr;97(4):1009-14
pubmed: 8655877
J Exp Med. 2005 Mar 21;201(6):937-47
pubmed: 15781584
Eur Respir J. 2014 Apr;43(4):1186-9
pubmed: 24311773
Thorax. 2013 Dec;68(12):1122-30
pubmed: 23882022
PLoS Comput Biol. 2008 Nov;4(11):e1000217
pubmed: 18989396
J Allergy Clin Immunol. 2015 Aug;136(2):497-500.e3
pubmed: 25772596
Nat Med. 2006 Sep;12(9):1023-6
pubmed: 16906156
J Allergy Clin Immunol. 2009 Aug;124(2):245-52, 252.e1-3
pubmed: 19596142
Lancet. 2002 Mar 9;359(9309):831-4
pubmed: 11897281
Am J Respir Crit Care Med. 2014 Mar 1;189(5):532-9
pubmed: 24471509
PLoS One. 2014 Jan 27;9(1):e85802
pubmed: 24475053
J Allergy Clin Immunol. 2019 Apr;143(4):1355-1370.e16
pubmed: 30316823
Am J Respir Crit Care Med. 2014 Dec 15;190(12):1373-82
pubmed: 25350863
Prog Med Virol. 1992;39:256-63
pubmed: 1317600
Clin Exp Allergy. 2019 Dec;49(12):1587-1597
pubmed: 31400236
Am J Respir Crit Care Med. 2019 Feb 15;199(4):465-477
pubmed: 30371106
J Allergy Clin Immunol. 2014 Dec;134(6):1402-1412.e7
pubmed: 25216987
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
J Allergy Clin Immunol. 2018 May;141(5):1607-1619.e9
pubmed: 28947081
Am J Respir Crit Care Med. 2014 Jul 15;190(2):145-54
pubmed: 24937476